The director of Oregon Health & Science University’s $1 billion Knight Cancer Institute resigned this week after just one year on the job, leaving OHSU with yet another interim leader in a key role.

Dr. Tom Sellers, who has served as director of the OHSU Knight Cancer Institute for the past year, has resigned. Sellers took the reins of the institute last March, when Dr. Brian Druker changed r ...

One of the world’s leading cancer researchers is stepping down as CEO of the Knight Cancer Institute at Oregon Health and Science University. Dr. Brian Druker handed in his resignation on ...

A new study reveals that the protein alpha-synuclein, known for its role in Parkinson’s disease, also contributes to the ...

Click here to read the full story. Dr. Brian Druker, who built the OHSU Knight Cancer Institute into a world class cancer research center, on Tuesday announced his resignation, saying that the ...

Fox Foundation, the Kuni Foundation; a Medical Student Research Award of the Melanoma Research Foundation; and a Ph.D. Scholar COVID-relief Award of the OHSU Knight Cancer Institute.

Scientists described the approval of capivasertib by the National Institute for Health and Care Excellence ... NICE's director of medicines evaluation, Helen Knight. The advanced type of the breast ...

A new drug that helps slow the spread of an incurable type of breast cancer has been approved for use in Britain's state-run National Health Service, officials said on Friday.

A new drug that helps slow the spread of an incurable type of breast cancer has been approved for use in Britain's state-run ...

The Institute of Cancer Research, London (ICR ... to personalise cancer care and improve quality of life for patients wherever possible”. Helen Knight, director of medicines evaluation at Nice, said ...